This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06). year follow-up.
A new artificial intelligence (AI) model designed by Scripps Research scientists could help clinicians better screen patients for atrial fibrillation (or AFib)—an irregular, fast heartbeat that is associated with stroke and heart failure.
A BMJ study out of Denmark provided alarming new insights into atrial fibrillation’s impact on patients’ future cardiovascular health, while highlighting the need to improve post-AFib heart failure and stroke prevention. The researchers analyzed 2000-2022 data from 3.5M The researchers analyzed 2000-2022 data from 3.5M
milla1cf Wed, 12/13/2023 - 10:24 December 13, 2023 — A new artificial intelligence (AI) model designed by Scripps Research scientists could help clinicians better screen patients for atrial fibrillation (or AFib)—an irregular, fast heartbeat that is associated with stroke and heart failure.
September is National Atrial Fibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Physicians have a crucial role in recognizing, diagnosing, and managing AFib to prevent its potentially life-threatening complications.
Looking at specific substances in the blood of people with atrial fibrillation, a type of irregular heartbeat, could help identify who's at risk for a stroke despite taking blood-thinning medication to prevent one, new research suggests.
September is National Atrial Fibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Physicians have a crucial role in recognizing, diagnosing, and managing AFib to prevent its potentially life-threatening complications.
Research Highlights: In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline, stroke or transient ischemic attack (TIA) in people younger than age 65 who had atrial fibrillation (AFib).
However, researchers noted that the trial was stopped prematurely and more research is necessary. However, researchers noted that the trial was stopped prematurely and more research is necessary.
"Based on the results from the admIRE clinical trial, we are confident that this innovation has the promise to deliver significant value and differentiated capabilities, and become an important tool for the treatment of AFib." 2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. In the U.S.,
The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures.1 Int J Stroke. Circulation Research. 2021 Feb;16(2):217-221.
Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort. Stroke is a major concern for millions of people living with atrial fibrillation, and as physicians, we strive to deliver better outcomes for these patients." Jennifer Currin, Ph.D.,
Signify Research has just released a deep-dive qualitative analysis of developments around the use of AI to analyze and interpret electrocardiograms (ECGs), one of the world’s most ubiquitous diagnostic tests for cardiac disease. Fertile Partnerships Ongoing research partnerships have driven much of recent developments seen in the market.
About a million possible cases of atrial fibrillation, a known risk for stroke, go undetected in Japan. The AI lineup currently covers both continuous ECG tracking and AFib detection. You are currently developing a new AI to detect AFib. Can you share the details of your study findings after testing your AFib AI detection model?
Abstract Introduction Atrial fibrillation (Afib) is a prevalent chronic arrhythmia associated with severe complications, including stroke, heart failure, and increased mortality. Results/Observation Current Afib detection methods, such as electrocardiography, have limitations in sensitivity and specificity.
Image courtesy: Getty Images christine.book Sat, 05/18/2024 - 14:26 May 18, 2024 — The Heart Rhythm Society ( HRS ) has announced the findings of three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation ( AFib ). doi:10.1001/jama.285.18.2370
Researchers analyzed 840 REDUCE-IT participants (10.3% Researchers analyzed 840 REDUCE-IT participants (10.3% However, like the original REDUCE-IT trial, IPE had higher treatment-related rates of AFib or flutter (7.4% absolute risk reduction for experiencing a first composite primary event (18.7%
and strokes and other CVDs are on the rise globally. One report projects a 50% increase in stroke-related deaths by 2050, with 10 million dying annually. Atrial fibrillation (AFib) cases have also surged, doubling from 28.3 Research points to low patient engagement as a predictive indicator of poor outcomes.
Introduction:Anticoagulation (AC) is the mainstay of thromboprophylaxis for stroke prevention in atrial fibrillation (AF) and is recommended. We compared the risk of stroke, GIB, and mortality in 5 years.Results:A total of 19,427 patients with UGIB who have AFIB received oral apixaban were identified. vs 11.9%, p=0.3).
The whole process can easily take 10-15 years and therefore patients may continue to be managed in sub-optimal manner for this duration of time even when there is available research to say that things could be done better. Today I wanted to talk about some troubling research in the field of AF. AF stands for atrial fibrillation.
19, 2024 Drinking multiple cups of coffee a day may help prevent cognitive decline in people withatrial fibrillation (AFib or AF), according to new research published in the Journal of the American Heart Association. Many myths are around, but our study found no reason to discourage or forbid a patient with AFib from drinking coffee.
Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.
What happened to top 10 cardiology research papers of 2023 ? In that sense, every year, we see more than 100s of RCT get released various research centers with varying credibility. most) of us lack the expertise of picking the genuine , winning research especially in the arena of new drugs and devices. Did we follow up ?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content